Azerra for mantle cell lymphoma
Azerra (ofatumumab) is a new antibiody against Chronic lymphocytic leukemia( CLL). Preclinical data suggest that it might be more effective than Rituxan in variety of lymphomas. In early clinical trials, ofatumumab demonstrated single-agent activity against chronic lymphocytic leukemia (CLL) and B-cell non-Hodgkin's lymphomas. It was approved by the US Food and Drug Administration for the treatment of CLL that is resistant to both fludarabine
Read more